Fundamental Analysis of ARS PHARMACEUTICALS INC(NASDAQ:SPRY) stock

Fundamental Rating

SPRY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 573 industry peers in the Biotechnology industry. SPRY has a great financial health rating, but its profitability evaluates not so good. SPRY has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SPRY has reported negative net income.

SPRY had a negative operating cash flow in the past year.

In the past 5 years SPRY always reported negative net income.

SPRY had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SPRY's Return On Assets of -20.20% is fine compared to the rest of the industry. SPRY outperforms 79.23% of its industry peers.

Looking at the Return On Equity, with a value of -20.84%, SPRY belongs to the top of the industry, outperforming 86.09% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-20.2%
ROE	-20.84%
ROIC	N/A

ROA(3y)-20.82%

ROA(5y)-44.89%

ROE(3y)-21.59%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRY so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, SPRY has more shares outstanding

SPRY has more shares outstanding than it did 5 years ago.

There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 112.21 indicates that SPRY is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 112.21, SPRY belongs to the best of the industry, outperforming 99.65% of the companies in the same industry.

SPRY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	112.21

ROIC/WACCN/A

WACC10.18%

2.3 Liquidity

SPRY has a Current Ratio of 32.82. This indicates that SPRY is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 32.82, SPRY belongs to the best of the industry, outperforming 97.36% of the companies in the same industry.

A Quick Ratio of 32.82 indicates that SPRY has no problem at all paying its short term obligations.

SPRY has a better Quick ratio (32.82) than 97.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	32.82
Quick Ratio	32.82

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SPRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -571.43%.

The Revenue for SPRY has decreased by -62.96% in the past year. This is quite bad

EPS 1Y (TTM)-571.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%27.78%

Revenue 1Y (TTM)-62.96%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%4900%

3.2 Future

SPRY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.04% yearly.

SPRY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 790.18% yearly.

EPS Next Y-18.55%

EPS Next 2Y-25.31%

EPS Next 3Y16.24%

EPS Next 5Y31.04%

Revenue Next Year41949%

Revenue Next 2Y7330.2%

Revenue Next 3Y2450%

Revenue Next 5Y790.18%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SPRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRY. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SPRY's earnings are expected to grow with 16.24% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-25.31%

EPS Next 3Y16.24%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SPRY!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (9/18/2024, 4:19:14 PM)

After market: 14.05 0 (0%)

14.05

+1 (+7.66%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.36B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-20.2%
ROE	-20.84%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	32.82
Quick Ratio	32.82
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-571.43%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-18.55%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-62.96%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ARS PHARMACEUTICALS INC (SPRY)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens